
GOP candidates for Texas Comptroller Christi Craddick and Don Huffines discuss why they're best for the job
While they have been in the race for months, former State Senator Kelly Hancock , R-North Richland Hills, is getting a jump start. On July 1, he will become the Acting Texas Comptroller after the outgoing Comptroller, Glenn Hegar, hired him as Chief Clerk. Hegar is set to become the Chancellor of the Texas A&M University System on July 1. Hancock also announced he's running for the job in the Republican primary next March and was backed by Governor Abbott.
In an interview for Eye On Politics, Craddick told CBS News Texas that her experience running statewide and overseeing a state agency are important. "I'm a Railroad Commissioner. I've just won my third election, so I'm the only statewide candidate who's won a primary. In fact, last cycle, I had four people in my primary against me and I won without a runoff. So not only that, I've won statewide across the state. I think that's a real positive people know who I am. I've been around in this state for a bit and run a good agency. First and foremost, as you walk into any business in the agency you audit, and see what is going on at that agency. How long is it taking to audit? How long is itaking to get refunds back to people. So I think those are real specifics that we need to make sure we're doing for taxpayers in the state."
Huffines, the former State Senator, said in an interview for Eye On Politics that he's taking his lead from the President. "I'm going to follow Donald Trump's leadership skills. We're going to bring a sense of urgency to Austin, Texas. I don't want to just DOGE the Comptroller's Office, I'm going to DOGE every agency I can in the State of Texas and what that means is auditing government. It means root out fraud, waste, and abuse and return the savings I find to the taxpayers, hopefully via property tax relief."
Candidate endorsements
Huffines, who challenged Governor Abbott in the GOP primary in March 2022, exchanged insults with him after Abbott endorsed Hancock. Huffines said in a post on X, "The political elite are manipulating the system to install another go along to get along lapdog as State Comptroller." When asked by CBS News Texas what he meant by that Huffines said, "I'm focused really on my campaign. I'm focused on traveling the state of Texas talking to voters. This was a manipulation of the process. There's no question about it by the establishment-Bush wing of the Republican party. I think the voters are going to see through that. That's why I'm going to win." Huffines is backed by Senator Ted Cruz.
In his announcement backing Hancock, the Governor said, "I endorse Kelly Hancock because I want a candidate who will actually win the election, not someone who's already lost an election to a Democrat." Huffines lost his State Senate seat to Democrat Nathan Johnson. When asked if he had a response to the Governor's statement Huffines said, "I'm focused on my race. I really am. When I won the Senate race, I'd done something that had never been done before: I knocked a 20 year plus incumbent (John Carona) in the Republican primary. I'm just focused on talking to the voters."
New task for Texas Comptroller
During this next year, the Comptroller's Office has a new function: implement the $1 billion school choice program featuring Education Savings Accounts or ESA's. The office must do so my June 15, 2026, so that the program can be ready to begin for the 2026-27 school year.
Eye on Politics reporter Jack Fink asked how important it is that the Comptroller's Office set-up the program on-time, on-budget, and make it easy for parents to navigate. Craddick said, "I think that's a priority. The legislature's school savings accounts, education savings accounts. I'm excited by it. If we don't do it right in the state, then we're going to have a real problem, and people will be mad and they should be. And it's real dollars. One billion dollars is a lot of money. This isn't an easy program to implement. You've got to understand procurement. You've got to go out and get those bids and get it implemented really quickly."
Huffines said ESA's were a priority for him while he served in the Senate and remain so today. "I'm excited about that. The Comptroller is in charge of the waiting list, the marketing of the program, implementing it with the five management companies that are going to be managing up to 100,000 ESA accounts. It's incredibly important that we don't stumble and we get this correct."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
AI Glasses Could Replace Smartphones, Zuckerberg Says
Meta Platforms (NASDAQ:META) is pushing a post-iPhone era with AI-powered glasses, recasting the smartphone as yesterday's interface. Investors are weighing in whether Zuckerberg's personal superintelligence vision can move from manifesto to mainstream. Warning! GuruFocus has detected 5 Warning Sign with META. He says the glasses will know users deeply, understand goals and help achieve them, and the company is piling on AI talent to build standalone versions that no longer need a phone. Right now the Ray-Ban smartglasses still lean on smartphones, but the roadmap is toward independent multimodal displays. Apple is defending the iPhone's role, while rivals are racing too: Amazon bought wearable startup Bee and Sam Altman is teaming with Jony Ive on a secret AI device. The shift in tone at Meta, from past hardware misses to a more urgent, existential pitch, is meant to turn skepticism into a narrative of necessity. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships
HOUSTON, TX - August 4, 2025 (NEWMEDIAWIRE) - Neutra Corp (OTC: NTRR) is hitting its stride with the purposeful growth in the clinical research industry with Neutra Life Sciences. Since the successful launch of its Site Management Organization (SMO), Neutra Life Sciences has strategically positioned itself for significant growth in the latter part of 2025 and the beginning of 2026. Neutra Life Sciences has solidified its multi-specialty platform by securing another suite of Joint Venture Partnerships. These new joint venture sites will be in the onboarding process: Podiatry Epic Foot & Ankle Centers ( Radiation Oncology Aspire Hospital Cancer Centers ( Dermatology Radiant Dermatology & Aesthetics Clinic ( Expanding into more specialties gives Neutra Life Sciences a significant advantage over other organizations in the space. This diversification in medical specialties allows NLS to serve a broader patient population and meet increasing demands in clinical research. Looking ahead, Neutra Life Sciences plans to continue expanding into additional specialties, further enhancing its ability to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. This strategic growth enables the company to play a critical role in accelerating the development of innovative treatments across a broader spectrum of therapeutic areas. "Our growth reflects the increasing demand for high-quality, integrated clinical research solutions," said Sydney Jim, President and CEO of Neutra Corp. "By aligning with established private practices and opening these new specialized sites, we are not only expanding our service offerings but also fostering innovation in patient care and research." Neutra Life Sciences remains focused on building a robust network of clinical research sites, delivering exceptional services to its partners, and advancing its mission to improve health outcomes through cutting-edge collaboration. For more information about the role of clinical research sites in advancing medicine, or to learn how to participate in a clinical trial, please contact Neutra Life Sciences via phone 281-598-0200 or email at info@ Neutra has made the strategic decision to divest its subsidiary, VIVIS Corporation, a hemp-based cannabis entity, as part of a broader shift toward long-term growth in the life sciences sector. This transition reflects the company's renewed focus on advancing its clinical research capabilities through its newly launched site management organization (SMO). By reallocating resources and leadership attention to the SMO business, Neutra aims to support high-quality clinical trials and expand its presence in the evolving healthcare and biotechnology landscape. This move underscores the company's commitment to innovation and delivering value in areas with greater regulatory stability and long-term market potential. About Neutra Corp Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being. Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options. Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone's past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof. View the original release on Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Loews's Q2 Earnings Jump As Investment Income And Insurance Underwriting Shine
Loews Corporation (NYSE:L) on Monday reported its second-quarter 2025 net income of $391 million, or $1.87 per share, compared to $369 million, or $1.67 per share, in the same period last year. Total revenue rose to $4.56 billion from $4.27 billion. CNA Financial Corporation (NYSE:CNA) contributed $274 million in net income attributable to Loews, down from $291 million a year ago. Core income rose 3% to $335 million. Net investment income for CNA increased due to a larger invested asset base, higher reinvestment rates, and favorable returns from limited partnerships and equities. Net written premiums grew 6%, while earned premiums increased 8%. Also Read: CNA's Property and Casualty underwriting income improved. Catastrophe losses fell to $62 million from $82 million. The combined ratio improved to 94.1% from 94.8%, while the underlying combined ratio was steady at 91.7%. Results included unfavorable development from legacy mass tort abuse reserves and higher investment losses. Boardwalk Pipelines posted net income of $88 million, up from $70 million. EBITDA rose 14% to $274 million. Results were driven by higher re-contracting rates, growth projects, and increased revenues from storage and parking, and lending. View more earnings on L Loews Hotels & Co. recorded net income of $28 million, down from $35 million. Adjusted EBITDA rose 11% to $109 million. Gains came from the opening of three new Universal Orlando Resort hotels and improved performance at Loews Arlington Hotel. Earnings declined due to lower equity income from joint ventures, higher depreciation and interest expenses, and reduced occupancy at the Loews Miami Beach Hotel during renovations. The Corporate segment reported $1 million in net income, compared to a loss of $27 million last year. This was helped by higher investment income from the parent company's trading portfolio. As of June 30, 2025, book value per share rose to $84.42 from $79.49 at year-end. Book value excluding AOCI increased to $91.66 from $88.18 as of December 31, 2024. The parent company held $3.4 billion in cash and investments and $1.8 billion in debt. Loews repurchased 2.9 million shares for $251 million in Q2 and an additional 0.1 million shares for $9 million between July 1 and August 1. Price Action: L shares closed 0.28% lower at 90.29 on Friday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Loews's Q2 Earnings Jump As Investment Income And Insurance Underwriting Shine originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.